These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Prolonged clinical remission of patients with severe pemphigus upon rapid removal of desmoglein-reactive autoantibodies by immunoadsorption. Eming R; Rech J; Barth S; Kalden JR; Schuler G; Harrer T; Hertl M Dermatology; 2006; 212(2):177-87. PubMed ID: 16484825 [TBL] [Abstract][Full Text] [Related]
28. Desmoglein 3-ELISA: a pemphigus vulgaris-specific diagnostic tool. Lenz P; Amagai M; Volc-Platzer B; Stingl G; Kirnbauer R Arch Dermatol; 1999 Feb; 135(2):143-8. PubMed ID: 10052398 [TBL] [Abstract][Full Text] [Related]
29. Influence of intravenous immunoglobulin therapy on serum levels of anti-beta 4 antibodies in ocular cicatricial pemphigoid. A correlation with disease activity. A preliminary study. Letko E; Bhol K; Foster SC; Ahmed RA Curr Eye Res; 2000 Aug; 21(2):646-54. PubMed ID: 11148601 [TBL] [Abstract][Full Text] [Related]
30. A sensitive and restricted enzyme-linked immunosorbent assay for detecting a heterogeneous antibody population in serum from people suffering from a new variant of endemic pemphigus. Abréu-Vélez AM; Yepes MM; Patiño PJ; Bollag WB; Montoya F Arch Dermatol Res; 2004 Mar; 295(10):434-41. PubMed ID: 14730452 [TBL] [Abstract][Full Text] [Related]
31. [Possible effect of interleukin-17 blockade in pemphigus foliaceus and neutrophilic diseases]. Kohlmann J; Simon JC; Kunz M; Treudler R Hautarzt; 2019 Aug; 70(8):641-644. PubMed ID: 31076811 [TBL] [Abstract][Full Text] [Related]
32. Are clinical phenotype and autoantibody profile always concordant in pemphigus? A study in a cohort of pemphigus patients. Cozzani E; Di Zenzo G; Riva S; Calabresi V; Sera F; Drosera M; Parodi A Eur J Dermatol; 2013; 23(1):40-8. PubMed ID: 23400331 [TBL] [Abstract][Full Text] [Related]
33. Explanations for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris. Mahoney MG; Wang Z; Rothenberger K; Koch PJ; Amagai M; Stanley JR J Clin Invest; 1999 Feb; 103(4):461-8. PubMed ID: 10021453 [TBL] [Abstract][Full Text] [Related]
34. Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. Li N; Zhao M; Hilario-Vargas J; Prisayanh P; Warren S; Diaz LA; Roopenian DC; Liu Z J Clin Invest; 2005 Dec; 115(12):3440-50. PubMed ID: 16284651 [TBL] [Abstract][Full Text] [Related]
35. Antibodies to the amino-terminal domain of desmoglein 1 are retained during transition from pemphigus vulgaris to pemphigus foliaceus. España A; Koga H; Suárez-Fernández R; Ohata C; Ishii N; Irarrazaval I; Teye K; Ohyama B; Hashimoto T Eur J Dermatol; 2014; 24(2):174-9. PubMed ID: 24776707 [TBL] [Abstract][Full Text] [Related]
36. Novel ELISA systems for antibodies to desmoglein 1 and 3: correlation of disease activity with serum autoantibody levels in individual pemphigus patients. Schmidt E; Dähnrich C; Rosemann A; Probst C; Komorowski L; Saschenbrecker S; Schlumberger W; Stöcker W; Hashimoto T; Bröcker EB; Recke A; Rose C; Zillikens D Exp Dermatol; 2010 May; 19(5):458-63. PubMed ID: 20163452 [TBL] [Abstract][Full Text] [Related]
37. Predominant IgG4 subclass in autoantibodies of pemphigus vulgaris and foliaceus. Futei Y; Amagai M; Ishii K; Kuroda-Kinoshita K; Ohya K; Nishikawa T J Dermatol Sci; 2001 May; 26(1):55-61. PubMed ID: 11323221 [TBL] [Abstract][Full Text] [Related]
38. Antibodies against desmoglein 3 (pemphigus vulgaris antigen) are present in sera from patients with paraneoplastic pemphigus and cause acantholysis in vivo in neonatal mice. Amagai M; Nishikawa T; Nousari HC; Anhalt GJ; Hashimoto T J Clin Invest; 1998 Aug; 102(4):775-82. PubMed ID: 9710446 [TBL] [Abstract][Full Text] [Related]
39. An 'n-of-1' placebo-controlled crossover trial of intravenous immunoglobulin as adjuvant therapy in refractory pemphigus vulgaris. Arnold DF; Burton J; Shine B; Wojnarowska F; Misbah SA Br J Dermatol; 2009 May; 160(5):1098-102. PubMed ID: 19222460 [TBL] [Abstract][Full Text] [Related]
40. Comparison of immunological parameters in patients with pemphigus vulgaris following rituximab and IVIG therapy. Feldman RJ; Christen WG; Ahmed AR Br J Dermatol; 2012 Mar; 166(3):511-7. PubMed ID: 21967407 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]